<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884556</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-030-001</org_study_id>
    <nct_id>NCT03884556</nct_id>
  </id_info>
  <brief_title>TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers</brief_title>
  <official_title>Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tizona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tizona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity,
      leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of
      immunosuppressive adenosine, which may change the tumor microenvironment and promote
      anti-tumor immune response.

      This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of
      TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and
      standard chemotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>1 cycle (each cycle is 21-28 days)</time_frame>
    <description>Assess the safety profile, dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TTX-030 when administered intravenously (IV) as a single agent and in combination with agents in specified regimens to subjects with advanced solid tumor malignancies or lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Cycles 1-3 (each cycle is 21-28 days)</time_frame>
    <description>Pharmacokinetics (PK) of TTX-030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD39 Expression</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Pharmacodynamic (PD) biomarkers relating to mechanism of action and immune responses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1, Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus gemcitabine plus nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTX-030</intervention_name>
    <description>Variable dose and schedule</description>
    <arm_group_label>Arm 1, Single Agent</arm_group_label>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab paclitaxel</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abreviated Inclusion Criteria

          1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or

               -  eligible to receive single-agent pembrolizumab as standard of care, or

               -  eligible to receive single-agent docetaxel as standard of care, or

               -  advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus
                  nab-paclitaxel as standard of care.

          2. Age 18 years or older, is willing and able to provide informed consent

          3. Evidence of measurable disease

          4. Life expectancy &gt; 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance
             status of 0-1

        Abbreviated Exclusion Criteria

          1. History of allergy or hypersensitivity to study treatment components. Patients with a
             history of severe hypersensitivity reaction to any monoclonal antibody.

          2. Use of investigational agent within 28 days prior to the first dose of study treatment
             and throughout the study

          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive
             therapy

          4. History of severe autoimmune disease

          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tizona Therapeutics, Inc.</last_name>
    <phone>888-585-2990</phone>
    <email>clinicaltrials@tizonatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tizona Therapeutics, Inc</last_name>
    <phone>888-585-2990</phone>
    <email>clinicaltrials@tizonatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Turrell, CCRP</last_name>
      <phone>916-734-3089</phone>
      <email>ceturrell@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reisy Guedes</last_name>
      <phone>305-243-8807</phone>
      <email>rxg957@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Center Oncology Hematology West P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays, M.A. CCRC</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Arywitz</last_name>
      <phone>732-235-8813</phone>
      <email>aa2039@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmos</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Reynolds</last_name>
      <phone>646-888-4404</phone>
      <email>reynoldm@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Erin Fredericksen</last_name>
      <phone>646-888-4440</phone>
      <email>frederie@mskcc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Eaton, BSN, RN, BC-RN</last_name>
      <phone>412-623-7957</phone>
      <email>mientkiewiczk@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center and Research Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <phone>901-683-0055</phone>
      <email>afletcher@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Line</last_name>
      <phone>615-329-7478</phone>
      <email>Cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-580-9521</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunstman Cancer Intitute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Conway</last_name>
      <phone>801-587-4021</phone>
      <email>hannah.conway@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Solid Tumors</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Relapsed/Refractory Lymphoma</keyword>
  <keyword>Prostrate Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>CD39</keyword>
  <keyword>Adenosine Pathway</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>PD-1</keyword>
  <keyword>Checkpoint Inhibitor</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

